Lupin partners with Zentiva to develop and market biosimilars, securing $50M tied to regulatory milestones and profit-sharing.

• Lupin will develop, manufacture, and supply biosimilars across agreed territories, retaining rights in USA and Canada.
• Zentiva to commercialize across Europe and CIS, using its strong regulatory and marketing infrastructure.
• The deal excludes any acquisition and involves no related-party interest or promoter involvement.